Daiichi Sankyo is to develop targeted cancer drugs using Kinaxo’s technology platforms, following the announcement that the two companies have entered into a long-term partnership for cancer research.

Daiichi Sankyo will employ Kinaxo’s chemical proteomics technologies, including Cellular Target Profiling, KinAffinity and PhosphoScout, for its various research programmes.

Cellular Target Profiling and KinAffinity are designed to identify native cellular targets of small molecule from biological samples, while PhosphoScout can dissect the cellular signal transduction pathways and their drug treatment response.

Kinaxo CEO Andreas Jenne said that the joint venture would enable development of novel medicines for cancer patients.